ImetelChat

On this video Dr. Bart Scott of Seattle Cancer Care Alliance speaks about new treatments for myelofibrosis, including imetelstat.

link: https://www.patientpower.info/video/exp ... cal-trials
(PatientPower, 17 October 2017)

I wish you all a happy 2018! Although pretty positive in various aspects, 2017 has been a rather flat year and has left us with some more waiting. Hopefully the next year will provide us with more concrete input for our discussions on the further development of imetelstat, here and elsewhere. For ma...

Here is CKTC's response to Hoosier's 2nd comment. by Curiosity Killed The Cat, SA 15 December 2018: The 4.7mg/kg is not a maintenance dose. That’s a dose reduction due to Grade 3 thrombocytopenia the patient developed around week 69. The patient also developed Grade 3 thrombocytopenia around week 8,...

tx, bio. I will look it up and bring it over.

Another comment from Hoosier regarding the MDS poster: Hooiser, SA 15 December 2017 Anybody notice the successful deployment of the 4.7mg/kg maintenance dose in the MDS study? Take a closer look at Fig. 3 of the ASH poster. The patient achieved TI at the 7.5mg dose, maintained their TI for nearly a ...

This is an interesting post from Hoosier (SA) regarding the latest MDS poster that was presented at ASH. He highlights the PR's and CR's, which we have wondered about. Hoosier, SA 12 December 2017 My (+) observations & interpretations of the MDS poster........ 1) No patient deaths attributable to Im...

Her a nice comment from Hoosier (SA) about Dr.Raza: "The video link is an absolute must watch and sets the table for what will be a coming out for Geron in MDS. The personal attachment and lifelong drive that Dr Raza will present will be more than we could hope for from Dr Scarlett. I now know why t...

DDD from Yahoo MB found this about Dr.Raza: Dr. Arza (speech Oct 2016): 'I’m happy to talk about all these novel clinical trials. One of these is something I wanted to explain. This very exciting approach. So, every chromosome on its end have these areas called telomeres and when a normal cell divid...

MENLO PARK, Calif., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that the company’s analyst and investor meeting to discuss imetelstat clinical data will take place in New York, N.Y., on Tuesday, December 19, 2017. The presentation will begin at 8:30 a.m. ET. Dr....

Pedmac, these are difficult questions to answer without getting into a lot of assumptions and speculations. I believe that Dr. Rasa is an important advocate. She has an international reputation regarding MDS. She will also speak on the Geron investors conference on December 19th at 8:30 a.m. ET. I a...

Here the link to Dr.Raza on TedX: https://www.youtube.com/watch?v=07rgtBzN4Qo

Thanks, bio, for bringing this excellent doctor to the attention of our community. We have an acknowledged MDS expert here, a Dr.Tefferi II. Her findings are important to patients, doctors and investors alike, so is her advocacy.

No worries, Sarg. I am used to submit my post and then, when reading back, figure out misspellings all the time. Sometimes it takes three times to get rid of those mistakes.

Thanks, Sarg. Great post!

Interesting article. It says in the conclusions: 'In conclusion, drugs in oncology achieving BTD are those in which an approximate doubling of OR or PFS rates compared with control arms and a reduction of HR by approximately half are achieved in either the single-arm or double-arm setting. The setti...

Thanks for sharing your thoughts, bio. Always appreciated.

Thanks for your interesting post. Let's see what the 'late breakers' will bring!

Thanks, bio. Should work now.

Some of my observations regarding the 4 abstracts: - impact of imet on MDS disease has been refined, while positive effect on TI and HI is confirmed; - the IMerge paper has been co-authored by 5 JnJ employees and 10 researchers/doctors from various hospitals, of which 7 from Europe and 3 from US (in...

And here are the links and conclusions for each abstract: 4256 Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge) Conclusions: In IPSS Low/Int-1 RBC transfusion dependent MDS patients relapsed...